Article Figures & Data
Figures
- Fig 1.
A, A VOI is seen in the gray matter of the frontal lobe in a healthy subject. B, MR spectroscopy was performed with a set of b-values (b=45 s/mm2 and b=1050 s/mm2).
- Fig 2.
A, A VOI is seen in the nonaffected frontal lobe in a patient with MELAS. B, MR spectroscopy was performed with a set of b-values (b=45 s/mm2 and b=1050 s/mm2).
- Fig 3.
A, A VOI is seen in the previously affected area of the patient with MELAS. B, MR spectroscopy was performed with a set of b-values (b=45 s/mm2 and b=1050 s/mm2).
Tables
- Table 1:
ADC values (mean) of metabolites in the gray matter of healthy subjects and in nonaffected areas of patients with MELAS
Values (×10−3mm2/s) Healthy Subjects (n = 15) Nonaffected Areas in Patients (n = 8) PValue Cho 0.20 ± 0.07 0.30 ± 0.08 .00002 Cr 0.20 ± 0.07 0.30 ± 0.05 .00002 NAA 0.21 ± 0.05 0.35 ± 0.06 .00001 - Table 2:
ADCs (mean) of metabolites in the gray matter of healthy subjects and in lesions of patients with MELAS
Values (×10−3mm2/s) Healthy Subject (n = 15) Lesions in Patients with MELAS (n = 10) PValue Cho 0.20 ± 0.07 0.27 ± 0.07 .0002 Cr 0.20 ± 0.07 0.31 ± 0.11 .0002 NAA 0.21 ± 0.05 0.29 ± 0.06 .0001
